The onsortium This project has received ... - AdMaiora Project
Transcript of The onsortium This project has received ... - AdMaiora Project
ADMAIORA will target an innovative paradigm that may revolu-
tionize OA treatment. Within the project time-frame (4 years),
the ambition is to achieve a 60% reduction of degeneration in
OA models, with respect to control (untreated) ones after 4
weeks, and a 90% reduction after 3 months. The Consortium will
evolve and merge technologies, that already showed a high
potential as experimental proof of concepts in various biomedi-
cal fields, and into a unique paradigm to accomplish this ambi-
tious objective. The ADMAIORA technologies will be assessed up
to the preclinical level.
The ADMAIORA Consortium will develop biosynthetic hydro-
gels integrated with piezoelectric nanoparticles enabling re-
sponsiviness to remote wireless ultrasound waves, and carbon-
based nanomaterials conferring higher mechanical and lubrica-
tion properties. Stem cells derived from adipose tissue, which
already demonstrated anti-inflammatory and regenerative prop-
erties, will be incuded in the nanocomposite hydrogel. Materials
and cells will be delivered in situ by an innovative handheld 3D
bioprinter, integrated in an arthroscopic tool. A custom brace
will be designed and equipped with ultrasound probes for both
monitoring the joint status and stimulating the implanted nano-
composite hydrogel. A dedicated App will allow a direct connec-
tion between patient and physician in an Internet of Things
framework.
Project Coordination Scuola Superiore Sant’Anna - The BioRobotics Institute, Italy
Leonardo Ricotti (Coordinator)
The Consortium This project has received funding from the
European Union’s Horizon 2020 Research and
Innovation Programme (Grant Agreement
No. 814413)
Partners Istituto Ortopedico Rizzoli, Italy - Principal Investigator (PI):
Gina Lisignoli
Bar-Ilan University, Israel - PI: Gilbert Daniel Nessim
PlasmaChem GMBH, Germany - PI: Carsten Jost
Image Guided Therapy SA, France - PI: Erik Dumont
Vimex Sp. z.o.o., Poland - PI: Tomasz Gapinski
Regentis Biomaterials LTD, Israel - PI: Aharon Wechsler
H&D Wireless AB, Sweden - PI: Pär Bergsten
Contacts
www.admaiora-project.com
@AdmaioraResearchProject @AdmaioraP [email protected]
ADMAIORA (ADvanced nanocomposite MAterI-
als fOr in situ treatment and ultRAsound-
mediated management of osteoarthritis) is a
research project funded under the Horizon
2020 EU Framework Programme (Call: H2020-
NMBP-TR-IND-2018, Research and Innovation
action), coordinated by The BioRobotics Insti-
tute of Scuola Superiore Sant’Anna (Pisa, Italy).
The aim of the project is to explore alternative
treatments for Osteoarthritis (OA), in order to
improve patients’ quality of life and their
healthy and active lifespan in the long-term, as
well as to reduce the healthcare costs for the
society.
THE PROJECT ADMAIORA stands out from other OA treatments being a multi-
approach therapy and aiming at a true disease-modifying and
patient-specific action. ADMAIORA aims, in the long-term, at
increasing the healthy and active lifespan of people affected by
OA. This results will be achieved by considerably slowing down
or even stopping the degeneration process, acting during OA at
early stage. The efforts will be directed towards achieving the
delay by several years or even avoiding surgical interventions for
total joint replacement. To make this challenging objective a
reality, the partners will work together to merge into a unique
workflow nanotechnologies, advanced materials, remotely phys-
ical stimulation, advanced manufacturing, wearable devic-
es and cloud platforms. In particular, ADMAIORA will explore
the potential of smart nanocomposite materials and stem cells,
in synergy with external physical stimuli (based on low-intensity
ultrasound), for stopping the degeneration of cartilage during
OA at early stages. The ADMAIORA target is to demonstrate the
ground-breaking potential of such a regenerative approach at a
preclinical level.
WHAT IS OSTEOARTHRITIS? Osteoarthritis (OA) is one of the most common joint disorders
worldwide, and currently affects ~ 40 million of EU citizens.
This disease involves the degeneration of cartilage and other
joint structures, and causing pain and disability especially in
middle-aged and elderly people. At present, it also implies
enormous direct and indirect costs for the European
healthcare systems.
Over the next decade, the number of people affected by OA is
expected to double due to population ageing and increased
rate of obesity (a risk factor for OA), resulting in a significant
burden at the society level. According to the United Nations,
by 2050, 130 million people will suffer from OA worldwide, of
whom 40 million will be severely disabled by the disease. This
represents an issue that is largely unsolved, at present.
Development of a biosynthetic hydrogel with smart functionali-
ties provided by carbon-based and piezoelectric nanomaterials;
Use of adipose-derived stem cells, to reduce inflammation and
to regenerate hyaline cartilage;
Development of a system for highly controlled ultrasound stimu-
lation of nanocomposite materials and cells;
Development of an innovative handheld 3D bioprinter, integrat-
ed in an arthoscopic tool;
Development of a IoT solution that will allow a direct connection
between patient, its knee and physician in an Internet of Things Cloud framework.
Project name: ADMAIORA
Grant number: 814413
Starting date: 1st January, 2019
Duration: 4 years
Funding: ~ 5,4 M€
Coordinator: Leonardo Ricotti
Partners: 8 from 6 countries
ADMAIORA will achieve its ambitious target by tackling the
following scientific and technological problems: